Skip to content
The Policy VaultThe Policy Vault

Votrient (pazopanib tablets) — Cigna

Uterine Sarcoma

Initial criteria

  • Patient age ≥ 18 years
  • Patient has recurrent or metastatic disease

Approval duration

1 year